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Objective: To assess the feasibility of routine isolation and expansion of amniotic fluid derived
mesenchymal stem cells (AF-MSC) in fetuses diagnosed with isolated congenital diaphragmatic hernia
(CDH).
Study design: Redundant AF samples of fetuses with CDH and normal fetuses were obtained. Cell colonies
weremechanically selected for each sample. Proliferation capacitywas expressed as population doubling
time (PDT). Cell lines were further characterizedwith flowcytometry, differentiation assays and qRT-PCR
(OCT4 and NANOG). After cell labeling with LacZ in vivo tracking was performed after fetal tracheal
injection in rabbits.
Results: Fourteen consecutive CDH samples (median gestational age (GA) of 32.9 weeks; IQR: 27.8–34.3
weeks) and seven control samples (30 weeks; IQR: 28.9–34.4 weeks) were obtained. PDT was similar in
both groups (45.4 h1.9 vs. 52.3 h3.4;NS). AF-MSCs expressed a typical mesenchymal CD marker
profile. Clones could be differentiated in osteogenic, adipogenic and chrondrogenic lineages. Expression
of multipotency markers was low in all cell lines. We confirmed the presence of injected cells inside the
fetal lung three days after intratracheal injection.
Conclusion: Routine isolation and expansion of AF-MSCs in CDH is feasible and cell lines generated were
comparable to those of control samples. AF-MSCs from affected fetuses could potentially be used in
future stem cell therapy.
ã 2014 Elsevier Ireland Ltd. All rights reserved.Introduction
Mesenchymal stem cells (MSC) are cells with a self-renewal
capacity and the ability to differentiate intomesodermal cell types,
such as adipogenic, osteogenic and chondrogenic cells. MSCs were
initially isolated from adult bone marrow [1], but they have been
isolated from numerous sources of adult tissues, as well as from
fetal and extra-embryonic tissues [2–4]. Considering the ethical
constraints for using embryonic stem cells (ESC), MSCs are anuven – Division Of Woman
ogy, Fetal Medicine Unit –
344215; fax: +32 16 344205.
st).
rved.interesting alternative for cell therapy and tissue engineering.
Furthermore MSCs, unlike ESCs, do not appear to form teratoma
when injected in vivo and their immunomodulatory capacities
reduce an immunologic response of the host after transplantation
[5].
The amniotic fluid is a rich source of various differentiated and
stem cell populations originating from different organ systems of
the developing fetus [6–9]. More recently, a distinct population of
cKit (CD117) positive cells was described, possessing the ability to
differentiate into cells outside the mesodermal lineage [10].
These broad multipotent cells are well-characterized, differenti-
ate to various cell lineages belonging to the 3 germ layers and
their therapeutic potential has been explored both using in vitro
as well as in vivo experiments [11]. However, in order to obtain
mesenchymal progenitors, simpler methodologies, which do not
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[6]. Likewise, we recently reported on the routine isolation of
AF-MSCs following mechanical selection in early mid trimester
amniotic fluid samples of structurally normal fetuses [12].
Cell therapy has been suggested in the management of
congenital malformations, including congenital diaphragmatic
hernia (CDH). CDH is a rare birth defect with an incomplete closure
of the diaphragm resulting in the herniation of abdominal organs
into the thorax, thereby interfering with pulmonary development.
The resulting pulmonary hypoplasia of both lungs leads to
potentially fatal ventilatory insufficiency and pulmonary hyper-
tension after birth. Despite advances in both neonatal care, as well
as the potential benefit of antenatal therapy a substantial part of
fetuses with severe CDH will not survive after birth. There is early
evidence of a beneficial effect of AF-MSCs on the developing lung
as demonstrated in the nitrofen rat model [11]. If this would be
confirmed in higher species and clinical applications are contem-
plated, onewould need to routinely isolate and expand AF-MSCs at
the moment of diagnosis, which typically would be in the late
second or early third trimester. Also, the isolation of lung
progenitors could provide new insights regarding the etiology of
CDH, since this is still largely unknown [13,14]. There is an
increasing evidence that certain candidate genes (such as, chicken
ovalbumin upstream promoter-transcription factor II (COUP-TFII),
Wilms tumor 1 (WT1) and GATA binding protein 4 5GATA4) or
signaling pathways (retinoid acid pathway) could play an
important role [13]. Cytogenetic analysis of amniotic fluid stem
cells could be useful in order to further unravel the underlying
causes of this condition.
Theoretically, the developmental aberrations and a decreased
surface area of conducting airways could influence the amount of
mesenchymal cells that are shed from the lungs into the amniotic
fluid. This might alter theMSC population in the amniotic fluid and
could potentially influence the isolation capability.
Therefore we set up a study to investigate the feasibility of
routine isolation and expansion of AF-MSC. Our second objective
was to evaluate if such cell lines could be used in vivo, e.g., by
administration into the developing fetal airways.
Materials and methods
Clinical sample collection
Redundant amniotic fluid (around 5–10ml) from clinical AF
samples, e.g., taken at the time of assessment or at fetal surgery
from fetuses with an isolated CDH was used. Typical time points
were either late diagnostic amniocentesis or fetoscopic endolu-
minal tracheal occlusion (FETO) for balloon insertion or balloon
removal [15]. Controls were redundant fluid samples from
structurally normal fetuses that underwent amniotic fluid
sampling at the time of other diagnostic or fetal surgery
procedures in the second or third trimester, such as fetoscopic
laser photocoagulation for twin-to-twin transfusion syndrome
(TTTS) or intrauterine transfusion for fetal anemia.
Cell culture
After filtration (40mm strainer) and centrifugation (240RCF,
5min) the cells were seeded in a tissue culture treated petridish
and allowed to attach. Incubation was done at 37 C in a 5%
humidified CO2 chamber for expansion. Cell culture medium
consisted of a-MEM (GIBCO1 Invitrogen, Ghent, Belgium), 15%
fetal bovine serum (FBS) (GIBCO1 Invitrogen), 1% L-glutamine
(Invitrogen), 1% penicillin/streptomycin (Invitrogen) and 18%
Chang B and 2% Chang C (Irvine Scientific, Brussels, Belgium).After a few days in culture, separate cell colonies
(4 colonies/sample) were mechanically picked up under inverted
microscope using fine-tipped pipettes. The aspirated cells of each
colony were re-seeded into an individual well of a 96-well plate.
Cells were allowed to reach 70% confluence andwere expanded for
further experiments. At each passage, cells were detached by
exposing the cell plate to trypsin/EDTA solution
(Sigma–Aldrich, St. Louis, MO, USA). Cells were counted manually
using a cell counter chamber and with each passage, 25103 cells
were reseeded in a single well of a six-well plate. Proliferation
capacity was evaluated with growth curves expressing population
doubling time (PDT= (t1 t0) log 2/log(number of cells at t1/
number of cells at t0))
Surface marker analysis with flow cytometry
After expansion, early passage (4–6) AF-MSCs were used for
characterization with fluorescent activated cell sorting (FACS) to
evaluate the surface marker expression profile. Antibodies (CD45,
CD34, CD73, CD90, CD105, CD44, CD117, HLA-DR, HLA-ABC (BD
Biosciences, Erembodegem, Belgium) and CD29 (Acris, Herford,
Germany)) were conjugatedwith either fluorescein isothiocyanate
(FITC) or phycoerythrin (PE). At least 105 cells were incubated for
30min at 4 C for both the antibody as well as the appropriate
isotype control. Unstained cells were used to determine the
background autofluorescence. Cell analysis was performed with a
FACSort cytometer (BD Biosciences) using Cell Quest software;
offline data interpretation was done using FlowJo software (Tree
Star, Ashland, OR, USA).
In vitro differentiation assays
Early passage (5–8) AF-MSCs were evaluated for differentia-
tion capacities into osteogenic, adipogenic and chondrogenic cell
lineages. Osteogenic differentiationwas induced in 70% confluent
cultures by the addition of a commercially available differentia-
tion medium (GIBCO1 Invitrogen) for 21 days. Alizarin staining of
the calcified extracellular matrix deposition was used to confirm
the formation of osteoblasts. Adipogenic differentiation was
induced in a 100% confluent culture into eight-chamber slides
(Nunc). The cells were submitted to cyclic changes (every 3 days)
with induction and maintenance medium. Induction medium
consisted of DMEM low glucose (Invitrogen), dexamethasone
(1mM), indomethacin (100mM), 3-isobutyl-L-methyl-xanthine
(0.5mM), human recombinant insulin (10mg/ml), FBS (10%),
penicillin and streptomycin (1%) for 14 and 21 days. Maintenance
medium consisted of DMEM with the addition of only FBS,
antibiotics and human recombinant insulin (10mg/ml). Oil Red O
staining was used for determination of adipogenic differentiation.
Chondrogenic differentiation was induced in high-density pellet
mass cultures for 14 days. These cultures were initiated in a
24-well plate by seeding a 20ml droplet of cell suspension
containing 400,000 cells in PBS. The cells in the droplet were
allowed to attach without medium for three hours, thereafter the
cells were cultured in the normal medium described above for
24h. The next day the medium was replaced by commercially
available differentiation medium (GIBCO1 Invitrogen) specific for
chrondrogenic differentiation. Chondrogenesis was confirmed
with Alcian Blue staining.
Quantitative real-time polymerase chain reaction (qRT-PCR)
The gene expression of OCT4 and NANOG, which are considered
multipotency markers were analyzed using qRT-PCR. Total RNA
was obtained using TriPure isolation reagent (Roche Diagnostics,
Vilvoorde, Belgium) according to the manufacturer’s guidelines
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spectrophotometer (NanoDrop Technologies, Wilmington, NC,
USA). Reverse transcription to synthesize cDNA out was performed
using TaqMan Reverse Transcription Reagents (Applied Biosytems,
Gent, Belgium). Real-time quantitative PCR analysis was carried
out on the ABI Prism 7000 detection system (Applied Biosystems,
Foster City, CA, USA) using Platinum SYBR Green qPCR supermix-
UDG (Invitrogen). GAPDH was used as a housekeeping gene to
normalize mRNA levels. RNA extracted from human embryonic
stem cells (hESC) and differentiated human umbilical vein
endothelial cells (HUVEC) served as positive and negative controls
respectively. The following primers for the selected genes were
used: OCT4: FW: 50-GATGGCGTACTGTGGGCCC-30, RV: 50-
TGGGACTCCTCCGGGTTTTG-30; NANOG: FW: 50- CAGAAGGCCT-
CAGCACCTAC-30, RV: 50-ATTGTTCCAGGTCTGGTTGC-30, GAPDH:
FW: 50-GCCTTCCGTGTCCCCACTGC-30, RV: 50-CAATGCCAGCCC-
CAGCGTCA-30.
Cell preparation for in vivo experiments
To allow tracking of the AF-MSCs, cells were transduced with a
lentiviral transfer plasmid encoding a nuclear localized beta-
galactosidase (LacZ) under control of a ubiquitous CBA promotor
[16]. Transduction was performed by adding vectors to the culture
medium at a multiplicity of infection of 10 [12]. Successful
transduction was verified after 4 passages by histochemical X-gal
staining.
In vivo experiment
We used the fetal rabbit model, which is often used for the
study of lung development as well as forced lung development by
tracheal occlusion [17,18]. This model can also be used for tracheal
injection [19]. In brief, time-mated pregnant rabbits (hybrid of
Dendermonde and New Zealand White) were operated at 28 days
of gestation. After midline laparotomy and hysterotomy the fetal
head was exteriorized. After exposure of the trachea by sharp
dissection, 1.0106 cells were injected into the trachea through a
26 gauge catheter, followed by tracheal occlusion [19]. At term (31
days) the does were euthanized, the fetuses were harvested and
the fetal lungs were embedded in OCT to obtain frozen sections.
The presence of LacZ positive cells was confirmed by histochemical
X-gal staining and Paracarmine counterstaining.
Statistical analysis
Data were analyzed with Prism for Mac version 6.0b (Graphpad
software, San Diego, CA, USA). Continuous data were expressed as
means and standard deviation, if normally distributed, otherwise
as medians and interquartile range (IQR). We used Student’s t-test
or aWilcoxon signed rank test to compare quantitative data with a[(Fig._1)TD$FIG]
Fig. 1. Proliferation capacity. (a) mean population doubling time (and standard error) fo
defined as (t1 t0) log 2/log(number of cells at t1/number of cells at t0); (b) percentanormal and skewed distribution, respectively. A p-value of below
0.05 was considered statistically significant.
Results
Sample collection and isolation of AF-MSCs
Fourteen consecutive samples of fetuses with isolated CDH
were collected at a median gestational age of 32.9 weeks (IQR:
27.7–34.3 weeks). Four patients were sampled twicewith at least 4
weeks interval. During the same time periodwe collected 7 control
samples (median GA: 30 weeks; IQR: 28.9–34.4 weeks). In all
samples four clones were mechanically selected and expanded, as
such yielding 56 CDH and 28 control clones [12]. There were no
differences between CDH and control samples regarding the time
period between cell seeding and mechanical selection, median
days 9 (7–10) and 8 (7–14), respectively.Meanpopulation doubling
time was similar in both groups (45.4 h13.0 h vs. 49.8 h14.3 h;
p=0.21; Fig. 1a), as well as the number of passages before reaching
senescence (Fig. 1b). In cases that were sample repeatedly we did
not observe any differences in mean population doubling time
related to the timing of sampling (early 49.1 h13.8 h vs. late
42.1 g9.5 h; p =0.09).
Surface marker analysis
We did not observe any difference in surface marker expression
between the two groups. Cell lines were positive for the typical
mesenchymal surface markers: CD73, CD105, and CD90. CD90
expression was more variable between clones, but always positive.
Cellswere positive forHLA-ABC aswell as adhesionmarkers such as
CD44andCD29. In all cells therewasnoexpressionofhematopoietic
markers as CD34, CD45 and HLA-DR. CD117 (cKit) expression was
variable but in general low in both groups (Fig. 2 and Table 1).
In vitro differentiation assays
Thecellscouldbesuccessfullydifferentiatedintomesodermalcell
lineages. Osteogenesis with deposition of calcium was confirmed
with Alizarin staining (Fig. 3). Chondrogenic differentiation was
confirmedwithAlcianBluestaining(Fig.3).Wecouldalsoobservethe
formation of intracellular vacuoles positive with Oil Red O staining.
However, even after 21 days in adipogenic culture conditions, the
vacuoles were small and not as abundant as is typically reported for
instance in adipose tissue derived stem cells (ADSC) (Fig. 3).
Quantitative real-time polymerase chain reaction (qRT-PCR)
The expression of pluripotency markers Oct4 and Nanog was
consistently low in our cells lines, i.e., less than 1% of the
expression values observed in the positive control (hESC).r CDH and control samples, expressed in relation to the passage number. PDT was
ge clones that are still proliferating in relation to the increasing passage number.
[(Fig._2)TD$FIG]
Fig. 2. Surface marker expression. Each dot represents a single sample, [TD$INLINE] CDH fetuses and [TD$INLINE] control fetuses. For each surface marker median and IQR are also displayed.
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After transduction with the lentiviral vector, 98% of the cells
were positive for LacZ confirmed by a nuclear localized blue color
(Fig. 4a). Furthermore, injected cells could be identified on frozen
sections of the lung three days after injection into the trachea
(Fig. 4b and c).
Comment
We used an established protocol to perform routine isolation of
AF-MSCs from AF samples of fetuses with congenital diaphrag-
matic hernia [12]. Despite the more advanced gestational age at
sampling we found similar growth and differentiation potential of
the isolated clones to what we previously observed in early mid
trimester samples [12]. This observation is in contrast to what was
reported earlier, i.e., that amniotic fluid from a more advanced
gestational age would be less suitable to start a successful culture,
because it would have a lower amount of MSCs [20]. Also, the
presence of CDH itself did not have impact on the feasibility of
culturing of AF-MSCs, as there were no differences compared with
AF samples fromnormal fetuses sampled late in pregnancy. Finally,
in order to evaluate the potential of these cells for in vivo
applications, they showed similar tropism to AF-MSCs derivedTable 1
Median and (IQR) of % positive cells for each surface marker analyzed with FACS in
CDH and control fetuses.
CDH (% positive cells) Controls (% positive cells)
HLA-DR 0.8 (0.5–1.1) 0.5 (0.4–0.6)
CD45 0.9 (0.7–1.2) 0.7 (0.5–0.8)
CD34 0.6 (0.4–0.9) 0.5 (0.4–0.6)
CD73 95.6 (89.5–99.1) 98.3 (96.9–99.5)
CD90 61.4 (25.4–93.1) 85.4 (54.4–99.0)
CD29 91.6 (84.5–98.1) 95.7 (91.7–98.9)
CD105 84.9 (56.1–95.5) 95.2 (51.4–98.6)
HLA-ABC 94.6 (83.7–98.3) 96.7 (91.7–99.1)
CD44 97.0 (93.1–99.3) 98.8 (94.9–99.6)
CD117 1.2 (1.0–2.6) 1.3 (0.5–4.4)from healthy fetuses and we were able to locate the cells in the
distal airways of the injected fetuses.
In the last decade it has become clear that amniotic fluid
contains a heterogeneous population of progenitors that originate
from different organ systems [6,21,22]. The relative contribution
from the different origins to this population varies throughout
gestation [21]. This may explain the variability between the cell
clones in expansion capacity, surface marker expression and
differentiation potential [6,23]. Furthermore, cellular heterogene-
ity could also be explained by isolation and culturing conditions
and the up/down regulation of certain signaling pathways. This
was recently reported for Wnt in relation to adipogenic
differentiation [23]. In the current series we also observed that
adipogenic differentiation is less abundant than in ADSCs. Another
possible explanation for this could be the presence of inhibitory
factors such as Pref-1 in the amniotic fluid. This decreases the
responsiveness to adipogenic stimuli as was also reported in cord
blood plasma [24].
Cell transduction with identification markers such as LacZ
allowed us to trace the injected cells throughout the fetus, and this
could be used in further in vivo experiments evaluating potential
modulating effects on the pulmonary development. On the other
hand, a recent report by Pederiva et al. suggested that the beneficial
effect of stem cells in CDH related pulmonary disease results from
paracrine factors rather than true engraftmentof thedeliveredcells
[11,25]. It is therefore possible that autologous therapy is not
imperative, which is particularly important given the potential
limitationofautologouscell therapy lies in the fact that toobtain the
same dose/fetal weight ratio used in animal experiments the
amount of cells for human applications is several times higher [11].
Considering the population doubling time, together with the
limited therapeutic window this seems a major hurdle.
On the other hand, a routine isolation and expansion protocol in
CDH patients could also be interesting in the production of
homologous tissue engineered grafts [26]. In this context of patient
tailored tissue engineering, an autologous source of cells is highly
desirable as it can prevent subsequent rejection of the graft after
transplantation. The heterogeneity on the other hand implies that
each individual sample may need eventually extensive in vitro
[(Fig._3)TD$FIG]
Fig. 3. Differentiation assays. Oil Red O staining for adipogenic differentiation (a) AF-MSC and (b) adipose tissue derived stem cells; (c) Alizarin staining for osteogenic and (d)
Alcian Blue staining detecting chondrogenesis. Negative controls of undifferentiated AF-MSC stained with (e) Oil Red O (f) Alizarin and (g) Alcian Blue staining.
[(Fig._4)TD$FIG]
Fig. 4. Cell transduction. (a) In vitro X-gal staining, blue nuclei confirming cell
transduction with beta-galactosidase. (b) and (c) frozen sections of a term rabbit
lung, injectedcells canbe identifiedbyX-gal stainingandare indicatedbythearrows.
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This characterization process is labor and time consuming and
requires more research before it can reach a clinical applicability.
Recent advances with techniques such as micro-array or micro
RNA analysis could potentially facilitate the identification of
specific cell markers allowing an early selection of more promising
clones [23].
In conclusion with this series we have shown that routine
isolation and expansion of AF-MSC seems feasible in fetuses with
CDH. Yet, based on the large heterogeneity and the current
available characterization techniques, antenatal autologous cell
therapy remains a challenge.
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